Checkpoint Therapeutics Inc

-0.09 (-2.78%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)255.74M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.09 Million
Adjusted EPS-$0.15
See more estimates
10-Day MA$3.40
50-Day MA$3.49
200-Day MA$3.08
See more pivots

Checkpoint Therapeutics Inc Stock, NASDAQ:CKPT

2 Gansevoort Street, 9th floor, New York, New York 10014
United States of America
Phone: +1.781.652.4500
Number of Employees: 10


Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in New York, NY.